BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, Ling R, Cammarata S; PROCEED Study Group. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother 2017;72:3471-80. [PMID: 29029278 DOI: 10.1093/jac/dkx329] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Cottreau JM, Christensen AB. Newly Approved Antimicrobials. Orthop Nurs 2020;39:53-8. [PMID: 31977743 DOI: 10.1097/NOR.0000000000000633] [Reference Citation Analysis]
2 Dagher M, Fowler VG Jr, Wright PW, Staub MB. A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay? Open Forum Infect Dis 2020;7:ofaa151. [PMID: 32523971 DOI: 10.1093/ofid/ofaa151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shortridge D, Flamm RK. Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections. Clinical Infectious Diseases 2019;68:S200-5. [DOI: 10.1093/cid/ciz003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Giordano PA, Pogue JM, Cammarata S. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis 2019;68:S223-32. [PMID: 30957167 DOI: 10.1093/cid/ciz006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chahine EB, Dougherty JA, Thornby KA, Guirguis EH. Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance? Ann Pharmacother 2021;:10600280211031390. [PMID: 34259076 DOI: 10.1177/10600280211031390] [Reference Citation Analysis]
6 Saran S, Rao NS, Azim A. New and promising anti-bacterials: Can this promise be sustained? J Anaesthesiol Clin Pharmacol 2020;36:13-9. [PMID: 32174651 DOI: 10.4103/joacp.JOACP_113_19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hook EW 3rd, Golden MR, Taylor SN, Henry E, Tseng C, Workowski KA, Swerdlow J, Nenninger A, Cammarata S. Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study. Sex Transm Dis 2019;46:279-86. [PMID: 30985632 DOI: 10.1097/OLQ.0000000000000971] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 9.5] [Reference Citation Analysis]
8 Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB. A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrob Agents Chemother 2018;62:e02580-17. [PMID: 29530858 DOI: 10.1128/AAC.02580-17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
9 Bassetti M, Labate L, Melchio M, Robba C, Battaglini D, Ball L, Pelosi P, Giacobbe DR. Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Expert Opin Pharmacother 2021;:1-14. [PMID: 34882041 DOI: 10.1080/14656566.2021.2010706] [Reference Citation Analysis]
10 Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ. Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. Infect Dis Ther 2018;7:197-217. [PMID: 29605887 DOI: 10.1007/s40121-018-0198-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
11 Bassetti M, Melchio M, Giacobbe DR. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Rev Anti Infect Ther 2021;:1-8. [PMID: 34913817 DOI: 10.1080/14787210.2021.2020098] [Reference Citation Analysis]
12 Tanvir SB, Qasim SSB, Latimer J, Qamar Z, Niazi FH. The Efficacy and Adverse Events of Delafloxacin for Treating Acute Bacterial Skin and Skin Structure Infections: A Systematic Review and Meta-Analysis. J Pharm Bioallied Sci 2020;12:S538-45. [PMID: 33149517 DOI: 10.4103/jpbs.JPBS_154_20] [Reference Citation Analysis]
13 Eckmann C, Tulkens PM. Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. J Antimicrob Chemother 2021;76:iv9-iv22. [PMID: 34849999 DOI: 10.1093/jac/dkab351] [Reference Citation Analysis]
14 Ma YX, Wang CY, Li YY, Li J, Wan QQ, Chen JH, Tay FR, Niu LN. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections. Adv Sci (Weinh) 2020;7:1901872. [PMID: 31921562 DOI: 10.1002/advs.201901872] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 18.3] [Reference Citation Analysis]
15 Tulkens PM, Van Bambeke F, Zinner SH. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clin Infect Dis 2019;68:S213-22. [PMID: 30957164 DOI: 10.1093/cid/ciy1079] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
16 Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Interest. Open Forum Infect Dis 2018;5:ofy220. [PMID: 30349845 DOI: 10.1093/ofid/ofy220] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
17 Al-Tawfiq JA, Momattin H, Al-Ali AY, Eljaaly K, Tirupathi R, Haradwala MB, Areti S, Alhumaid S, Rabaan AA, Al Mutair A, Schlagenhauf P. Antibiotics in the pipeline: a literature review (2017-2020). Infection 2021. [PMID: 34606056 DOI: 10.1007/s15010-021-01709-3] [Reference Citation Analysis]
18 Lee AS, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, Harbarth S. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers 2018;4:18033. [PMID: 29849094 DOI: 10.1038/nrdp.2018.33] [Cited by in Crossref: 252] [Cited by in F6Publishing: 231] [Article Influence: 63.0] [Reference Citation Analysis]
19 Almarzoky Abuhussain SS, Goodlet KJ, Nailor MD, Nicolau DP. Optimizing skin and skin structure infection outcomes: considerations of cost of care. Expert Rev Pharmacoecon Outcomes Res 2018;18:235-44. [PMID: 29521147 DOI: 10.1080/14737167.2018.1450142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Sexton ME, Langston AA, Wiley Z, Nowak MD, Jacob JT. Antimicrobial Stewardship in the Hematopoietic Stem Cell Transplant Population. Curr Treat Options Infect Dis 2018;10:249-62. [DOI: 10.1007/s40506-018-0159-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Saravolatz LD, Pawlak JM, Wegner C. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid. Journal of Antimicrobial Chemotherapy 2020;75:2605-8. [DOI: 10.1093/jac/dkaa209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Voulgaris GL, Voulgari ML, Falagas ME. Developments on antibiotics for multidrug resistant bacterial Gram-negative infections. Expert Rev Anti Infect Ther 2019;17:387-401. [PMID: 31006284 DOI: 10.1080/14787210.2019.1610392] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
23 Bassetti M, Eckmann C, Peghin M, Carnelutti A, Righi E. When to switch to an oral treatment and/or to discharge a patient with skin and soft tissue infections. Curr Opin Infect Dis 2018;31:163-9. [PMID: 29324505 DOI: 10.1097/QCO.0000000000000434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
24 Shortridge D, Pfaller MA, Streit JM, Flamm RK. Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019). J Glob Antimicrob Resist 2020;23:278-83. [PMID: 33068780 DOI: 10.1016/j.jgar.2020.09.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Vrancianu CO, Dobre EG, Gheorghe I, Barbu I, Cristian RE, Chifiriuc MC. Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 2021;9:730. [PMID: 33807464 DOI: 10.3390/microorganisms9040730] [Reference Citation Analysis]
26 Bassetti M, Righi E, Pecori D, Tillotson G. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiol 2018;13:1081-94. [PMID: 29764190 DOI: 10.2217/fmb-2018-0067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
27 Vlachaki I, Vacchelli M, Zinzi D, Falla E, Jiang Y, Mantopoulos T, Nathwani D. Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis. BMC Infect Dis 2021;21:1036. [PMID: 34610820 DOI: 10.1186/s12879-021-06736-x] [Reference Citation Analysis]
28 Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist 2021;3:dlaa114. [PMID: 34223066 DOI: 10.1093/jacamr/dlaa114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
29 Giacobbe DR, Labate L, Vena A, Bassetti M. Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. Curr Opin Infect Dis 2021;34:109-17. [PMID: 33395093 DOI: 10.1097/QCO.0000000000000708] [Reference Citation Analysis]
30 Liapikou A, Cilloniz C, Palomeque A, Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs 2019;24:221-31. [PMID: 31657962 DOI: 10.1080/14728214.2019.1685494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
31 Wittke F, Vincent C, Chen J, Heller B, Kabler H, Overcash JS, Leylavergne F, Dieppois G. Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid. Antimicrob Agents Chemother 2020;64:e00250-20. [PMID: 32747361 DOI: 10.1128/AAC.00250-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother 2018;73:1439-51. [PMID: 29425340 DOI: 10.1093/jac/dkx543] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
33 Bassetti M, Peghin M, Castaldo N, Giacobbe DR. The safety of treatment options for acute bacterial skin and skin structure infections. Expert Opin Drug Saf 2019;18:635-50. [PMID: 31106600 DOI: 10.1080/14740338.2019.1621288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
34 Scott LJ. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections. Drugs 2020;80:1247-58. [PMID: 32666425 DOI: 10.1007/s40265-020-01358-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
35 Nascimento-Carvalho CM. Delafloxacin as a treatment option for community-acquired pneumonia infection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34346823 DOI: 10.1080/14656566.2021.1957098] [Reference Citation Analysis]
36 Motos A, Yang H, Yang M, Torres A. Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia. Expert Opin Pharmacother 2019;20:1439-48. [PMID: 31095426 DOI: 10.1080/14656566.2019.1617852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Saravolatz LD, Stein GE. Delafloxacin: A New Anti–methicillin-resistant Staphylococcus aureus Fluoroquinolone. Clinical Infectious Diseases 2019;68:1058-62. [DOI: 10.1093/cid/ciy600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
38 Chao CM, Weng TS, Chen YH, Lai CC, Lin WT. Anti-MRSA quinolones for acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34753366 DOI: 10.1080/14787210.2022.2004119] [Reference Citation Analysis]
39 Mat Rani NNI, Mustafa Hussein Z, Mustapa F, Azhari H, Sekar M, Chen XY, Mohd Amin MCI. Exploring the possible targeting strategies of liposomes against methicillin-resistant Staphylococcus aureus (MRSA). Eur J Pharm Biopharm 2021;165:84-105. [PMID: 33974973 DOI: 10.1016/j.ejpb.2021.04.021] [Reference Citation Analysis]
40 Jean SS, Gould IM, Lee WS, Hsueh PR; International Society of Antimicrobial Chemotherapy (ISAC). New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs 2019;79:705-14. [PMID: 30972660 DOI: 10.1007/s40265-019-01112-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
41 Righi E, Carnelutti A, Vena A, Bassetti M. Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. Infect Drug Resist 2018;11:479-88. [PMID: 29670380 DOI: 10.2147/IDR.S142140] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
42 Bassetti M, Hooper D, Tillotson G. Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis 2019;68:S233-40. [PMID: 30957169 DOI: 10.1093/cid/ciy1080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
43 O'Riordan W, McManus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, Lawrence L, Liang S, Cammarata S; PROCEED Study Group. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study. Clin Infect Dis 2018;67:657-66. [PMID: 29518178 DOI: 10.1093/cid/ciy165] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
44 Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN. Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone. J Clin Microbiol 2018;56:e00339-18. [PMID: 29848564 DOI: 10.1128/JCM.00339-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Andrei S, Valeanu L, Chirvasuta R, Stefan MG. New FDA approved antibacterial drugs: 2015-2017. Discoveries (Craiova) 2018;6:e81. [PMID: 32309599 DOI: 10.15190/d.2018.1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
46 Lan SH, Lai CC, Lu LC, Chang SP, Huang HT. Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist 2019;12:1415-23. [PMID: 31213859 DOI: 10.2147/IDR.S202160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Jorgensen SCJ, Murray KP, Lagnf AM, Melvin S, Bhatia S, Shamim MD, Smith JR, Brade KD, Simon SP, Nagel J, Williams KS, Ortwine JK, Veve MP, Truong J, Huang DB, Davis SL, Rybak MJ. A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Infect Dis Ther 2020;9:89-106. [PMID: 31983021 DOI: 10.1007/s40121-019-00278-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
48 Kollef MH, Betthauser KD. New antibiotics for community-acquired pneumonia. Curr Opin Infect Dis 2019;32:169-75. [PMID: 30640820 DOI: 10.1097/QCO.0000000000000526] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
49 Shiu J, Ting G, Kiang TK. Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin. Eur J Drug Metab Pharmacokinet 2019;44:305-17. [PMID: 30324277 DOI: 10.1007/s13318-018-0520-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
50 Yeroushalmi S, Shirazi JY, Friedman A. New Developments in Bacterial, Viral, and Fungal Cutaneous Infections. Curr Dermatol Rep 2020;9:152-65. [PMID: 32435525 DOI: 10.1007/s13671-020-00295-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Bystritsky RJ. Cellulitis. Infect Dis Clin North Am 2021;35:49-60. [PMID: 33494874 DOI: 10.1016/j.idc.2020.10.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Golan Y. Current Treatment Options for Acute Skin and Skin-structure Infections. Clin Infect Dis 2019;68:S206-12. [PMID: 30957166 DOI: 10.1093/cid/ciz004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
53 Ocheretyaner ER, Park TE. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Expert Review of Anti-infective Therapy 2018;16:523-30. [DOI: 10.1080/14787210.2018.1489721] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]